Compare Crispr Therapeutics AG (CRSP) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Star Bulk Carriers Corp — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while Star Bulk Carriers Corp trades at $29.91 (market cap $3.54B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Star Bulk Carriers Corp for 24 Days on average.
| CRSP | SBLK | |
|---|---|---|
Market Cap | $4.88B | $3.54B |
Volume | 2,861,747 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $74.92 | $32.49 |
52-Week Low | $44.34 | $16.79 |
Typical Hold Time | 77 Days | 24 Days |
Enterprise Value | $3.30B | $4.22B |
Dividend Yield | — | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Star Bulk Carriers (SBLK) trades at $29.86, up 0.57% today, with a bullish technical signal from moving averages and a neutral RSI. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and a net income margin of 23.87%. Recent news highlights insider buying and a declared $0.90 dividend, reflecting confidence in the shipping sector's momentum.
The outlook for SBLK is positive, supported by robust earnings growth, attractive valuation metrics like a P/E of 11.95, and a high analyst buy consensus of 58.34%. Key risks include exposure to volatile shipping rates and macroeconomic pressures, but the company's solid cash flow and dividend policy offer shareholder value. Upside potential hinges on continued operational execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
